Cantor Fitzgerald set a $53.00 target price on Apellis Pharmaceuticals (NASDAQ:APLS) in a research report released on Monday morning. The firm currently has a buy rating on the stock.
A number of other analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Apellis Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, November 16th. JPMorgan Chase & Co. cut their price objective on shares of Apellis Pharmaceuticals from $38.00 to $34.00 and set an overweight rating on the stock in a research note on Wednesday, November 14th. ValuEngine raised shares of Apellis Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, November 1st. Finally, B. Riley increased their price target on shares of Apellis Pharmaceuticals from $27.00 to $40.00 and gave the stock a buy rating in a report on Thursday, September 13th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Apellis Pharmaceuticals has a consensus rating of Buy and a consensus target price of $38.67.
NASDAQ:APLS opened at $17.99 on Monday. The firm has a market capitalization of $1.02 billion and a PE ratio of -4.90. Apellis Pharmaceuticals has a 1-year low of $11.45 and a 1-year high of $32.00. The company has a current ratio of 14.90, a quick ratio of 14.91 and a debt-to-equity ratio of 0.14.
Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, November 13th. The company reported ($0.64) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.05. Research analysts predict that Apellis Pharmaceuticals will post -2.38 EPS for the current fiscal year.
In other news, major shareholder Morningside Venture Investment purchased 81,323 shares of the stock in a transaction that occurred on Friday, September 21st. The shares were purchased at an average cost of $19.48 per share, with a total value of $1,584,172.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel David O. Watson sold 15,776 shares of the stock in a transaction on Friday, September 14th. The stock was sold at an average price of $18.78, for a total transaction of $296,273.28. The disclosure for this sale can be found here. Corporate insiders own 9.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in APLS. TD Asset Management Inc. purchased a new stake in Apellis Pharmaceuticals during the second quarter worth $428,000. Victory Capital Management Inc. boosted its holdings in Apellis Pharmaceuticals by 150.2% during the second quarter. Victory Capital Management Inc. now owns 932,753 shares of the company’s stock worth $20,520,000 after buying an additional 559,913 shares in the last quarter. Jennison Associates LLC boosted its holdings in Apellis Pharmaceuticals by 50.5% during the second quarter. Jennison Associates LLC now owns 570,464 shares of the company’s stock worth $12,550,000 after buying an additional 191,313 shares in the last quarter. Alps Advisors Inc. purchased a new stake in Apellis Pharmaceuticals during the second quarter worth $1,786,000. Finally, State of Wisconsin Investment Board purchased a new position in Apellis Pharmaceuticals during the second quarter valued at $810,000. 55.94% of the stock is currently owned by hedge funds and other institutional investors.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Read More: Google Finance
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.